| Q28744655 | Bound water at protein-protein interfaces: partners, roles and hydrophobic bubbles as a conserved motif |
| Q61797528 | CIC protein instability contributes to tumorigenesis in glioblastoma |
| Q37413655 | DHX33 Transcriptionally Controls Genes Involved in the Cell Cycle |
| Q26741797 | DUBbing Cancer: Deubiquitylating Enzymes Involved in Epigenetics, DNA Damage and the Cell Cycle As Therapeutic Targets |
| Q54979307 | EGF upregulates RFPL3 and hTERT via the MEK signaling pathway in non‑small cell lung cancer cells. |
| Q35900578 | Extracellular Signal-Regulated Kinases Modulate DNA Damage Response - A Contributing Factor to Using MEK Inhibitors in Cancer Therapy |
| Q38093445 | Key role of ERK1/2 molecular scaffolds in heart pathology. |
| Q55078845 | Overexpression of ST5, an activator of Ras, has no effect on β-cell proliferation in adult mice. |
| Q38757884 | Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer. |
| Q35230130 | Ras, ROS and Proteotoxic Stress: A Delicate Balance |
| Q33351823 | Ras, an actor on many stages: posttranslational modifications, localization, and site-specified events. |
| Q26744308 | The MST/Hippo Pathway and Cell Death: A Non-Canonical Affair |
| Q38085500 | The role of tumour–stromal interactions in modifying drug response: challenges and opportunities |
| Q39687000 | Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma |
| Q36405845 | p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model. |